Sunflower Pharma gains NMPA approval for fexofenadine oral suspension

Sunflower Pharmaceutical Group Co., Ltd. announced today that its subsidiary has received a drug registration certificate from the National Medical Products Administration (NMPA) for fexofenadine hydrochloride oral suspension. This approval is for a chemically synthesized drug (Category 3) with specifications of 120ml:0.72g, designated as a prescription drug. The drug's approval number is H20255183.

The newly approved fexofenadine hydrochloride oral suspension is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children aged 2 years and older, and adults. It also treats chronic idiopathic urticaria, easing skin symptoms like itching and reducing the number of wheals in patients aged 6 months and older.

This approval is expected to expand the company's product pipeline and market coverage in the anti-allergic segment. The company plans to expedite the mass production and commercialization of this product, while emphasizing quality and process control throughout the production lifecycle.